Beacon Award for Women Leaders in Oncology

2024 Call for Nominations

Deadline: May 31, 2024
The AIM-HI Beacon Award for Women Leaders in Oncology recognizes outstanding women leaders in all sectors of the health and life science industry, who have made a significant impact on advancing cancer treatment, detection, and diagnosis for patients worldwide, through the development and commercialization of novel technologies, advocacy, and/or implementation of public policy.

The 2024 Beacon Award prize recipient will be awarded an authentic gold medal and honored at a Luncheon Award Ceremony at the National Press Club in Washington, DC on October 18, 2024.

To Submit Your Nomination:

- Nominations are submitted by an online form at AIM-HIaccelerator.org/Nominate
- Please submit all required documents.
- The Award Selection Committee reviews all complete submissions.
The AIM-HI Beacon Award for Women Leaders in Oncology

Nominations

Nominees will have played an essential role in helping develop, approve and commercialize innovative cancer drugs, therapies or diagnostics and that are impacting patients’ lives or have significant promise to do so in the future. Two conominees may be considered if they demonstrate shared leadership responsibilities for the development of oncology discoveries, technologies and/or products.

Nominations from academia, the investment community, industry, government, or other organizations are welcome and require:

- Nominee’s CV (ten pages maximum) containing employment history, previous honors/awards and contact information (including cell phone)
- A Letter of Nomination (no more than 2,000 words) describing the Nominee’s success, barriers she overcame, contributions and impact she has made for cancer patients from commercialization of technology, product, and/or public policy. The letter should indicate the Nominator’s position and brief biographical information
- **Nomination closes on May 31, 2024**
The AIM-HI Beacon Award for Women Leaders in Oncology

Award Selection Process

All nomination information will be kept confidential, and be reviewed and evaluated by the distinguished Beacon Award Selection Committee, comprising of physician-scientists, successful entrepreneurs, and prominent business leaders in the health & life sciences industry.

Nominations will be assessed according to the following criteria:

• Sustained commitment and leadership for cancer research, development and commercialization of innovative products
• Advocacy for and implementation of public policy to benefit cancer patients
• Encouragement, advocacy and inspiration of other women
• Impact on cancer patients, their families and community

The Selection Committee will carefully consider the merit and impact all the nominees and select the most deserving awardee(s) each year.
The AIM-HI Beacon Award
Previous Awardees

Monica M. Bertagnolli, M.D.
2023 Awardee
Director,
National Cancer Institute

“I am deeply honored to accept this Beacon Award, and I do so with profound gratitude for the recognition. Throughout my career, I have been guided by an unwavering commitment to advancing the fight against cancer, and this award serves as a testament to the collective efforts of countless individuals who have shared this mission. I would like to thank the AIM-HI Accelerator Fund and the selection committee for recognizing the importance of these initiatives in illuminating the path towards innovative treatments for cancer patients.”

- Monica M. Bertagnolli, M.D.

Anna D. Barker, Ph.D.
2022 Awardee
Chief Strategy Officer,
Lawrence J. Ellison Institute for Transformative Medicine
Distinguished Visiting Fellow,
Complex Adaptive Systems,
Arizona State University

“It is my honor to accept this inaugural award on behalf of the patients I serve in all my efforts. A special thanks to my many colleagues and scientists who did the work to achieve the goals of the programs cited by this award – all of whom contributed unselfishly to their success. I also applaud Dr. Ba, the NFCR, and AIM-HI Accelerator Fund for recognizing the critical role of forward-looking and complex large-scale science like TCGA and GBM AGILE in fundamentally understanding cancer by empowering individual scientists, teams and increasing the rate of progress toward a future where cancer will be detected early and successfully treated or prevented for all patients.”

- Anna D. Barker, Ph.D.
About the AIM-HI Accelerator Fund

The AIM-HI Accelerator Fund (AIM-HI) is an independent 501(C)(3) non-profit organization, created in 2019 by the National Foundation for Cancer Research to provide oncology startups with the resources they need to drive innovative discoveries forward, out of the lab, to the clinics, and eventually to the people battling cancer. Our mission is to bridge the gap between research breakthroughs and clinical trials, with the ultimate goal of developing innovative cancer therapies and technologies that can save patients’ lives.

A TAX EXEMPT CHARITY
TAX ID#: 82-4322538
5515 Security Lane, Suite 1105
Rockville, MD 20852
www.AIM-HIaccelerator.org